Evaluation of Safety and Thrombolytic Effect of Ascending Doses of DS-9231 (TS23) in Subjects with Intermediate-Risk (sub-massive) Acute Pulmonary Embolism (PE)

Trial Profile

Evaluation of Safety and Thrombolytic Effect of Ascending Doses of DS-9231 (TS23) in Subjects with Intermediate-Risk (sub-massive) Acute Pulmonary Embolism (PE)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs TS 23 (Primary)
  • Indications Pulmonary embolism
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 21 Nov 2017 This trial has been Discontinued Hungary.
    • 14 Nov 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 11 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top